Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.
Melanoma|Neoplasm
DRUG: Karenitecin (BNP1350)
Overall Response, start of treatment until progressive disease
Objective Tumor Response Rate, Start of treatment to date of response|Duration of Response, Date of response to date of progressive disease|Overall Survival, Randomization to date of death from any cause|Progression Free Survival, Randomization to disease progression
The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.